https://go.evvnt.com/955983-0?pid=5248 Hyatt Regency Boston
1 Avenue de Lafayette
Boston, Massachusetts 02111
Lectures & Conferences
Following significant progress in obtaining structural insights from transcription factor-DNA (TF-DNA) complexes using techniques like cryo-electron microscopy, Biotech is continuing to pour investment into developing therapeutic interventions to address increased expression of specific transcription factor associated oncogenes and oncogene amplification in cancer.
The Transcription Factor-Directed Therapies Summit is the industry's first in-person conference on precision molecular oncology, supporting these efforts with cutting-edge scientific insights as industry leaders prioritize TF-directed medicines in its precision oncology tactics. With the FDA's recent approval of Welireg, the first-of-its-kind HIF-2 inhibitor paving the way for several other techniques in development ranging from small molecule inhibitors to PROTAC-based degraders, this is a vital moment for the discipline.
Be part of this unique forum highlighting multiple targeting strategies including inhibition of TF-cofactor protein-protein interactions, TF-DNA binding, allosteric modulators of TF, regulators of TF expression, and modulation of TF activity levels via ubiquitylation and subsequent proteasome degradation.
As an increasing number of drug candidates enter preclinical and clinical programs, join pioneers of TF medicine to examine the latest challenges faced in drugging these notoriously undruggable targets whilst harnessing novel discovery and screening technologies that are streamlining drug development and opening the field up to new therapeutics possibilities.
Conference + Workshop - Drug Developer: USD 3648.0,
Conference Only - Drug Developer: USD 2999.0,
Conference + Workshop - Standard: USD 4348.0,
Conference Only - Standard: USD 3599.0,
Conference + Workshop - Academic: USD 3148.0,
Conference Only - Academic: USD 2599.0
Speakers: Alex Federation, Co-Founder and Chief Executive Officer, Talus Bio, Alon Goren, Assistant Professor, University of California San Diego, Ben Amidon, Senior Director, Ikena Oncology, Brian Jones, Chief Scientific Officer, Cedilla Therapeutics, Erica Jackson, Executive Vice President - Target Biology, Scorpion Therapeutics, Geza Ambrus-Aikelin, Associate Director - Biology, Vividion Therapeutics, Jim Rotolo, Vice President and Head Of Translational Pharmacology and Research, Sapience Therapeutics Inc., Jody Mason, Professor, University of Bath, Joe Hyunsun, Founder and Chief Executive Officer, Pin Therapeutics, Kai Wang, Predictive Sciences, Oncogenesis Thematic Research Center, Bristol-Myers Squibb Co., Lila Ghamsari, Director - Discovery Science, Sapience Therapeutics Inc., Martin Eiler, Professor, University of Wurzburg, Matthew Oser, Assistant Professor of Medicine, Dana-Farber Cancer Institute, Melinda Day, Associate Director - Translation, Kronos Bio, Shaomeng Wang, Professor, University of Michigan, Taosheng Chen, Director - High Throughput Bioscience and Chemical Biology, St. Jude Children's Research Hospital